Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022)

Historic Long-Term Investments for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q2 2022 value amounting to $24.2 million.

  • ARS Pharmaceuticals' Long-Term Investments changed N/A to $24.2 million in Q2 2022 from the same period last year, while for Jun 2022 it was $24.2 million, marking a year-over-year change of. This contributed to the annual value of $64.8 million for FY2021, which is N/A changed from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Long-Term Investments of $24.2 million as of Q2 2022.
  • ARS Pharmaceuticals' 5-year Long-Term Investments high stood at $64.8 million for Q4 2021, and its period low was $24.2 million during Q2 2022.